PerClot Technology Acquisition (Details) (USD $)	12 Months Ended						0 Months Ended	3 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011 PerClot [Member]	Sep. 28, 2010 PerClot [Member] Trademarks [Member]	Sep. 28, 2010 PerClot [Member] Distribution And Manufacturing Right In Certain International Countries [Member]	Sep. 28, 2010 Starch Technology Purchase [Member]	Sep. 30, 2010 Starch Technology Purchase [Member]
Business Acquisition [Line Items]
Term of distribution agreement							15 years
Option to purchase certain remaining related technology							3 years
Cash paid for acquisition							$ 6,750,000
Number of shares issued as consideration for PerClot technology acquisition							209,000
Contingent payment							250,000
Additional contingent amounts paid if FDA regulatory and other commercial milestones are achieved							2,500,000
Initial aggregate consideration							8,000,000
Approximate value of restricted common stock issued for acquisition							1,000,000
Non-current assets for prepaid royalties							1,500,000
Deferred tax asset							145,000
Amortizable intangible assets					327,000	2,600,000	2,600,000
In-process research and development								3,500,000
Intangible asset useful life	14 years						15 years
Research and development	7,257,000	6,899,000	5,923,000	250,000
Expected future contingent payment amounts to be initially recorded as research and development expense							$ 2,500,000